BioCentury
ARTICLE | Clinical News

Bryostatin-1: Phase IIb amended

August 22, 2016 7:00 AM UTC

Neurotrope submitted to FDA an amended protocol for an ongoing double-blind, placebo-controlled, U.S. Phase IIb trial of 20 and 40 ug IV Bryostatin-1 given as 7 doses over 12 weeks in about 150 patien...